| Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption MM McDonald, WH Khoo, PY Ng, Y Xiao, J Zamerli, P Thatcher, W Kyaw, ... Cell 184 (5), 1330-1347. e13, 2021 | 273 | 2021 |
| Microbubble–sonosensitiser conjugates as therapeutics in sonodynamic therapy N Nomikou, C Fowley, NM Byrne, B McCaughan, AP McHale, JF Callan Chemical Communications 48 (67), 8332-8334, 2012 | 78 | 2012 |
| Androgen deprivation results in time‐dependent hypoxia in LNCaP prostate tumours: Informed scheduling of the bioreductive drug AQ4N improves treatment response L Ming, NM Byrne, SN Camac, CA Mitchell, C Ward, DJ Waugh, ... International journal of cancer 132 (6), 1323-1332, 2013 | 61 | 2013 |
| Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition NM Byrne, H Nesbitt, L Ming, SR McKeown, J Worthington, DJ McKenna British journal of cancer 114 (6), 659-668, 2016 | 59 | 2016 |
| Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities NM Byrne, MA Summers, MM McDonald JBMR plus 3 (3), e10125, 2019 | 33 | 2019 |
| Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression H Nesbitt, NM Byrne, SN Williams, L Ming, J Worthington, RJ Errington, ... Clinical Cancer Research 23 (7), 1797-1808, 2017 | 29 | 2017 |
| Nitric Oxide Up‐Regulates RUNX2 in LNCaP Prostate Tumours: Implications for Tumour Growth In Vitro and In Vivo H Nesbitt, G Browne, KM O'Donovan, NM Byrne, J Worthington, ... Journal of cellular physiology 231 (2), 473-482, 2016 | 23 | 2016 |
| Exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development J Feng, NM Byrne, W Al Jamal, JA Coulter Cancers 11 (12), 1989, 2019 | 20 | 2019 |
| Radiation response in the tumour microenvironment: Predictive biomarkers and future perspectives NM Byrne, P Tambe, JA Coulter Journal of Personalized Medicine 11 (1), 53, 2021 | 19 | 2021 |
| Cytometry of Anticancer Prodrug OCT1002 Activation and Targeting Using In Vitro and In Vivo Models of Tumour Hypoxia P Smith, M Wiltshire, H Nesbitt, N Byrne, L Ming, D McKenna, ... CYTO 2015, the 30th Congress of the International Society for Advancement of …, 2015 | 4 | 2015 |
| Targeting hypoxic prostate tumours using the novel hypoxia-activated prodrug OCT1002 inhibits expression of genes associated with malignant progression H Nesbitt, N Byrne, L Ming, J Worthington, R Errington, L Patterson, ... Ulster Medical Journal, The 86 (1), 11-11, 2016 | 3 | 2016 |
| Urethane dimethacrylate based photopolymerizable resins for stereolithography 3D printing: A physicochemical characterisation and biocompatibility evaluation G Pitzanti, V Mohylyuk, F Corduas, NM Byrne, JA Coulter, DA Lamprou Drug Delivery and Translational Research, 2023 | 2 | 2023 |
| Modulating tumour metabolism enhances gold nanoparticle radiosensitisation in HPV-negative head and neck cancer J Feng, V Pathak, NM Byrne, T Wang, C Yin, RJ Medina, JA Coulter Cancer Nanotechnology 14 (1), 33, 2023 | | 2023 |
| Identification of dormant prostate cancer cells in the skeleton in vivo and ex vivo NM Byrne, WH Khoo, N Mourad, JA Quinn, P Julian, S Shah, ... BJU INTERNATIONAL 118, 35-36, 2016 | | 2016 |
| Importance of the tumour microenvironment in the treatment response of prostate tumours NM Byrne Ulster University, 2014 | | 2014 |
| This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca. cf. ac. uk/97090/This is the author’s version of a work that … H Nesbitt, NM Byrne, N Williams, L Ming, J Worthington, RJ Errington | | |
| Targeting hypoxia in prostate cancer cells to increase treatment efficacy H Nesbitt, L Ming, N Byrne, S Mc Keown, J Worthington | | |
